Wang, Y., Rui, M., Guan, X., Cao, Y., & Chen, P. (2021). Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective. Front Med (Lausanne).
Chicago Stili AlıntıWang, Yingcheng, Mingjun Rui, Xin Guan, Yingdan Cao, ve Pingyu Chen. "Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective." Front Med (Lausanne) 2021.
MLA AlıntıWang, Yingcheng, et al. "Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective." Front Med (Lausanne) 2021.